Skip to main content
OpenTrials
Completed

NCT Number: NCT03381209

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.

The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Muscle Relaxation

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Medicine, Ain Shams University

Cairo, Egypt

About this study

The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight, and actual body weight. Reversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.

Time need for extubation (time from administration of sugammadex to extubation), and duration of stay in post anesthesia care unit (PACU), will be used as secondary outcome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients older than 18 years and under 45 years,
  • body mass index ≥ 40 kg/m2, with indication of bariatric surgery

Exclusion criteria

  • Patients with comorbid including: neuromuscular disease, renal impairment, and patients with difficult airway were excluded from this study.

Treatment and study plan

Sugammadex

Drug

sugammadex given based on 3 measurements of body weights

Other names: bridion

Primary outcomes

  1. Reversal Time

    Time frame: 5 minutes after sugammadex administration

    Reversal Time: time from administration of Sugammadex to train of four (TOF) ratio ≥ 0.9 will be used as primary outcome.

Secondary outcomes

  1. duration of stay in PACU

    Time frame: 60 minutes after admission to the PACU

    period of stay in the PACU

  2. Time need for Extubation

    Time frame: 10 minutes after sugammadex administration

    time from administration of sugammadex to extubation

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weights on Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Dec 21, 2017
Registry last updated
Dec 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.